EVMN insider ownership: who sold, why, and what they still hold

What stands out

Five insiders bought shares: Weegen Verduyn-van (1.56M shares, $25.0M), Cooperative LSP (1.56M shares, $25.0M) and Arthur Kirsch (10K shares, $133K), plus 2 more. These are the first purchases by current officers or directors in the filings on record.Weegen Verduyn-van: purchase, Nov 7, 2025 · Cooperative LSP: purchase, Nov 7, 2025 · Arthur Kirsch: purchase, Jul 7, 2026

A share of stake is shown for 0 of the 6 officers and directors who sold. 12 are left out

Left out: Luis Pena, Eugene Bauer, Gregory Moss, Kyle Carver, Jeegar Patel, Janice Drew, David Cohen, Robert Hopfner, Arthur Kirsch, Benjamin McGraw III, Weegen Verduyn-van and Cooperative LSP (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Luis Pena

President & CEO, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$551KDisclosed plan

Janice Drew

Chief of Dev. Operations

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$453KDisclosed plan

Kyle Carver

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$415KDisclosed plan

Jeegar Patel

Chief Scientific Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$413KDisclosed plan

Gregory Moss

Chief Business & Legal Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$325KDisclosed plan

All 6 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Jul 8, 2026Kyle Carver bought 1K shares ($13K).

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Kyle Carver Chief Financial Officer	1,000	$13.26	n/a	n/a	Jul 8, 2026	Jul 10, 2026

Outside holders, reported separately

Pivotal bioVenture Partners Fund I, L.P., RA CAPITAL MANAGEMENT, L.P. and Robert Hopfner reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Evommune, Inc. CEO selling stock?

Yes. Luis Pena sold 24K shares ($551K) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Evommune, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 100% of sales by value ran under 10b5-1 trading plans disclosed in the filings. A trading plan schedules sales in advance.

Are any Evommune, Inc. insiders buying?

Yes. 5 officers or directors reported 5 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold6 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Luis Pena President & CEO, Director	$551K 24K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Janice Drew Chief of Dev. Operations	$453K 20K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Kyle Carver Chief Financial Officer	$415K 18K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Jeegar Patel Chief Scientific Officer	$413K 18K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Gregory Moss Chief Business & Legal Officer	$325K 14K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
David Cohen Director	$123K 6.1K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Board members representing outside shareholders, reported separately: Robert Hopfner. Details

Outside holder, reported separately: Pivotal bioVenture Partners Fund I, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: RA CAPITAL MANAGEMENT, L.P. (an outside shareholder, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 12 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Luis Pena

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Luis Pena are complete.

President & CEO, Director

n/a

−24K

n/a

Vesting, gifts, unvested awards and holding lines for Luis Pena

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Luis Pena are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−28Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
394,830	$3.07	May 10, 2032	$4.0M
102,692	$3.58	Jan 12, 2033	$994K
192,114	$3.84	May 11, 2033	$1.8M
23,797	$1.71	Jan 5, 2034	$275K
290,774	$2.99	Dec 8, 2034	$3.0M
796,841	$16.00	Nov 4, 2035	$0
291,420	$26.77	Apr 15, 2036	$0

Estimate: options held × ($13.26 − strike price), using the most recent insider trade price on Form 4 (Jul 8, 2026), not a market close.

Eugene Bauer

Chief Medical Officer, Director

n/a

Vesting, gifts, unvested awards and holding lines for Eugene Bauer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eugene Bauer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−1.5Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
118,449	$3.07	May 10, 2032	$1.2M
30,807	$3.58	Jan 12, 2033	$298K
57,634	$3.84	May 11, 2033	$543K
7,139	$1.71	Jan 5, 2034	$82K
17,982	$2.99	Dec 8, 2034	$185K
100,000	$18.44	Dec 8, 2035	$0
51,117	$26.77	Apr 15, 2036	$0

Estimate: options held × ($13.26 − strike price), using the most recent insider trade price on Form 4 (Jul 8, 2026), not a market close.

Gregory Moss

Chief Business & Legal Officer

n/a

−14K

n/a

Vesting, gifts, unvested awards and holding lines for Gregory Moss

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gregory Moss are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−14Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
133,834	$3.07	Jul 14, 2032	$1.4M
35,323	$3.58	Jan 12, 2033	$342K
65,318	$3.84	May 11, 2033	$615K
8,090	$1.71	Jan 5, 2034	$93K
47,845	$1.71	Mar 21, 2034	$553K
114,552	$2.99	Dec 8, 2034	$1.2M
293,496	$16.00	Nov 4, 2035	$0
115,279	$26.77	Apr 15, 2036	$0

Estimate: options held × ($13.26 − strike price), using the most recent insider trade price on Form 4 (Jul 8, 2026), not a market close.

Kyle Carver

Chief Financial Officer

n/a

−18K

n/a

Vesting, gifts, unvested awards and holding lines for Kyle Carver

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kyle Carver are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−13Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
118,449	$3.07	May 10, 2032	$1.2M
30,807	$3.58	Jan 12, 2033	$298K
57,634	$3.84	May 11, 2033	$543K
7,139	$1.71	Jan 5, 2034	$82K
96,731	$2.99	Dec 8, 2034	$993K
279,408	$16.00	Nov 4, 2035	$0
98,946	$26.77	Apr 15, 2036	$0

Estimate: options held × ($13.26 − strike price), using the most recent insider trade price on Form 4 (Jul 8, 2026), not a market close.

Jeegar Patel

Chief Scientific Officer

n/a

−18K

n/a

Vesting, gifts, unvested awards and holding lines for Jeegar Patel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeegar Patel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−7.5Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
88,048	$3.58	Nov 3, 2032	$852K
22,900	$3.58	Jan 12, 2033	$222K
27,842	$3.84	May 11, 2033	$262K
5,306	$1.71	Jan 5, 2034	$61K
82,947	$2.99	Dec 8, 2034	$852K
179,619	$16.00	Nov 4, 2035	$0
69,315	$26.77	Apr 15, 2036	$0

Estimate: options held × ($13.26 − strike price), using the most recent insider trade price on Form 4 (Jul 8, 2026), not a market close.

Janice Drew

Chief of Dev. Operations

n/a

−20K

n/a

Vesting, gifts, unvested awards and holding lines for Janice Drew

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Janice Drew are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−5.1Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,408	$1.20	Oct 13, 2030	$186K
19,810	$1.20	Jan 24, 2031	$239K
48,010	$3.07	May 10, 2032	$489K
30,807	$3.58	Jan 12, 2033	$298K
53,795	$3.84	May 11, 2033	$507K
7,139	$1.71	Jan 5, 2034	$82K
39,321	$2.99	Dec 8, 2034	$404K
231,274	$16.00	Nov 4, 2035	$0
73,892	$26.77	Apr 15, 2036	$0

Estimate: options held × ($13.26 − strike price), using the most recent insider trade price on Form 4 (Jul 8, 2026), not a market close.

David Cohen

Director

n/a

−6.1K

n/a

Vesting, gifts, unvested awards and holding lines for David Cohen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Cohen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
61,356	$3.07	May 10, 2032	$625K
5,869	$3.84	May 11, 2033	$55K
5,869	$1.71	Jan 5, 2034	$68K
11,739	$2.99	Dec 16, 2034	$121K
37,960	$16.00	Nov 4, 2035	$0
15,673	$19.82	Jun 1, 2036	$0

Estimate: options held × ($13.26 − strike price), using the most recent insider trade price on Form 4 (Jul 8, 2026), not a market close.

Robert Hopfner

Director

n/a

Vesting, gifts, unvested awards and holding lines for Robert Hopfner

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Hopfner are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Arthur Kirsch

Director

n/a

Vesting, gifts, unvested awards and holding lines for Arthur Kirsch

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Arthur Kirsch are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
37,960	$16.00	Nov 4, 2035	$0
15,673	$19.82	Jun 1, 2036	$0

Estimate: options held × ($13.26 − strike price), using the most recent insider trade price on Form 4 (Jul 8, 2026), not a market close.

Benjamin McGraw III

Director

n/a

Vesting, gifts, unvested awards and holding lines for Benjamin McGraw III

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Benjamin McGraw III are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
17,609	$1.20	Oct 13, 2030	$212K
61,356	$3.07	May 10, 2032	$625K
5,869	$3.84	May 11, 2033	$55K
5,869	$1.71	Jan 5, 2034	$68K
8,804	$2.99	Dec 16, 2034	$90K
37,960	$16.00	Nov 4, 2035	$0
15,673	$19.82	Jun 1, 2036	$0

Estimate: options held × ($13.26 − strike price), using the most recent insider trade price on Form 4 (Jul 8, 2026), not a market close.

Weegen Verduyn-van

Director

n/a

Vesting, gifts, unvested awards and holding lines for Weegen Verduyn-van

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Weegen Verduyn-van are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Cooperative LSP

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Cooperative LSP are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Cooperative LSP

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Cooperative LSP are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Holdings and share of stake for Evommune, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$2.3M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $2.3M across 100,854 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $2.3M · 100%

Taxes

69,117 shares ($1.2M) were withheld by the company for taxes, which isn't a market sale.

Purchases · 5 buyers (5 trades)

5 officers and directors bought shares in this period, in 5 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 5 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Luis Pena President & CEO, Director	24K	$551K	100%	24%	Jun 1, 2026 to Jun 22, 2026
Janice Drew Chief of Dev. Operations	20K	$453K	100%	20%	Jun 22, 2026 to Jun 22, 2026
Kyle Carver Chief Financial Officer	18K	$415K	100%	18%	May 28, 2026 to May 28, 2026
Jeegar Patel Chief Scientific Officer	18K	$413K	100%	18%	Jun 1, 2026 to Jun 22, 2026
Gregory Moss Chief Business & Legal Officer	14K	$325K	100%	14%	May 28, 2026 to May 28, 2026
David Cohen Director	6.1K	$123K	100%	5%	Jun 2, 2026 to Jun 2, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$0	$0	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$740K	$740K	$0	$0
Jun 2026	$1.5M	$1.5M	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 13, 2025	Sold	Held Oct 13, 2026	Still held
Robert Hopfner ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Robert Hopfner are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Robert Hopfner Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Hopfner are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Known gaps and uncertainty12 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Evommune, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology64 filings on record, 64 filed in the 12-month period, and how we read them

All 64 Forms 3, 4 and 5 on record for Evommune, Inc. (SEC CIK 2044725), filed from Nov 5, 2025 to Jul 10, 2026; 64 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (1)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Derek DiRocco		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Evommune, Inc. insiders sold $2.3M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Evommune, Inc. CEO selling stock?

Why are Evommune, Inc. insiders selling?

Are any Evommune, Inc. insiders buying?

The evidence

Taxes

Purchases · 5 buyers (5 trades)

Sales by month